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background:  This study evaluated differences in medical costs associated with clinical endpoints from randomized trials that compared 
the new oral anticoagulants (NOACs), dabigatran, rivaroxaban, apixaban, and edoxaban (60 mg) to warfarin for treatment of patients with 
nonvalvular atrial fibrillation (NVAF).
Methods:  The rates of efficacy and safety clinical events for warfarin were estimated from the published data of the NOAC vs. warfarin 
clinical trials. Incremental medical costs to a U.S. health payer of clinical events were obtained from published literature and inflation 
adjusted to 2013 costs. Medical costs were evaluated and compared for each NOAC vs. warfarin. Univariate and multivariate Monte Carlo 
sensitivity analyses were additionally conducted.
Results:  Based on differences in clinical event rates associated with use of each of the NOACs when compared with warfarin, the annual 
medical cost avoidances associated with use of dabigatran, rivaroxaban, apixaban, and edoxaban were estimated at -$204, -$140, -$495, 
and -$340 per patient, respectively. Of the 10,000 random Monte Carlo simulation cycles, 94.2%, 85.1%, 100.0%, and 99.9% had a cost 
reduction <$0 for dabigatran, rivaroxaban, apixaban, and edoxaban 60 mg, respectively.
conclusion:  Medical costs are reduced when NOACs are used instead of warfarin for the treatment of NVAF, with apixaban being 
associated with the greatest medical cost avoidance.
Outcomes
Dabigatran-150mg 
vs. warfarin ($/patient-
yr)
Rivaroxaban
vs. warfarin ($/patient-
yr)
Apixaban
vs. warfarin ($/
patient-yr)
Edoxaban-60mg
vs. warfarin ($/patient-yr)
Primary Efficacy Endpoints
Ischemic or uncertain type of 
stroke -$126 -$40 -$37 $0
Hemorrhagic stroke -$161 -$104 -$132 -$124
Systemic embolism -$9 -$32 -$3 -$9
Secondary Efficacy Endpoints
Myocardial infarction $71 -$88 -$30 -$19
Pulmonary embolism or deep-
vein thrombosis $11 -$1 -$2 $1
Safety Endpoints
Major bleedings-excluding 
hemorrhagic stroke $12 $122 -$280 -$181
Clinically relevant non-major 
bleedings $0 $2 -$5 -$8
Other minor bleedings -$1 $0 -$6 -$1
Total Medical Cost Difference -$204 -$140 -$495 -$340
